Puma Biotechnology | PBYI - Ebitda


Puma Biotechnology reported $729K in EBITDA for its fiscal quarter ending in June of 2024.





Ebitda Change Date
Agios Pharmaceuticals USD -120.31M 4.82M Dec/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Amgen USD 5.14B 775M Dec/2025
Biogen USD 649.7M 76.5M Mar/2026
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Daiichi Sankyo JPY 101.6B 22.81B Mar/2025
Esperion Therapeutics USD -9.93M 24.99M Sep/2025
Exelixis USD 258.29M 15.43M Mar/2026
Gilead Sciences USD 3.02B 1.01B Dec/2025
Glaxosmithkline GBP 4.75B 1.52B Sep/2025
Incyte USD 367.97M 46.53M Mar/2026
MacroGenics USD 21.95M 55.39M Sep/2025
Moderna USD -790M 582M Dec/2025
Novartis USD 5.3B 530M Mar/2026
Pfizer USD 5.99B 5.23B Mar/2026
PTC Therapeutics USD -70.99M 91.62M Dec/2025
Puma Biotechnology USD 729K 11.36M Jun/2024
Regeneron Pharmaceuticals USD 1.2B 718.4M Dec/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Sarepta Therapeutics USD -252.2M 84.16M Dec/2025
Takeda JPY 150.25B 297.88B Mar/2026
TG Therapeutics USD 51.69M 19M Dec/2025
Ultragenyx Pharmaceutical USD -99.43M 57.35M Dec/2025
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024
Vertex Pharmaceuticals USD 1.19B 195.3M Mar/2026